With a market cap of $18.4 billion, Insulet Corporation (PODD) is a global leader in developing innovative insulin delivery ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...